Andexxa mechanism of action6/15/2023 ![]() ![]() Connolly SJ, Crowther M, Eikelboom JW, et al. ICU admission, discharge, and triage guidelines: a framework to enhance clinical operations, development of institutional policies, and further research. Nates JL, Nunnally M, Kleinpell R, et al. Princeton, NJ: Bristol-Myers Squibb Company, and New York, NY: Pfizer Inc. Titusville, NJ: Janssen Pharmaceuticals, Inc. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Hankey GJ, Stevens SR, Piccini JP, et al. Truven Health Analytics, DOAC Market Data Report. Truven Bleeding Events Report: Commercial, Medicare, & Medicaid Populations. Boston, MA: Alexion Pharmaceuticals, Inc. ANDEXXA ® (coagulation factor Xa (recombinant), inactivated-zhzo). ‡ RASUNOA study design: Based on a prospective, multicenter, observational substudy of patients with nontraumatic DOAC-related intracerebral hemorrhage (n=45). † ARISTOTLE study design: Based on a double-blind, double-dummy, randomized clinical trial comparing apixaban with warfarin in patients with AF (N=18,201). * ROCKET AF study design: Based on a multinational, randomized, double-blind, double-dummy clinical trial comparing rivaroxaban with warfarin in patients with atrial fibrillation (AF) (N=14,264). Gastrointestinal bleeds account for 39%-56% of all bleeding events in rivaroxaban- and apixaban-treated patients 9,10.In a prospective, multicenter, observational study, substantial hematoma expansion (defined as a volume increase of ≥33% or ≥6 mL) occurred in approximately, 40% of intracerebral hemorrhage patients taking DOACs 8‡.In nonvalvular atrial fibrillation clinical trials, 48% of rivaroxaban-treated patients (ROCKET AF Trial*) and 45% of apixaban-treated patients (ARISTOTLE Trial †) with intracranial hemorrhage died within 30 days 6,7.Here are some facts about these patients: ![]()
0 Comments
Leave a Reply. |